Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 10/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20315026 | 0.85 | RPS6KA3 (0.38) | IDO1OPRL1ADRA2AADRA2BADRA2C | |
| SCHEMBL22870362 | 0.77 | RPS6KA3 (0.35) | RPS6KA3 | |
| SCHEMBL21973762 | 0.77 | CYP11B2 (0.43) | OPRL1ADRA2AADRA2BADRA2CRPS6KA3 | |
| SCHEMBL25147294 | 0.74 | RPS6KA3 (0.44) | OPRL1RPS6KA3CHRNB2CHRNA4 | |
| SCHEMBL25220711 | 0.74 | OPRL1 (0.34) | IDO1OPRL1CYP17A1RPS6KA3 | |
| SCHEMBL30488141 | 0.74 | OPRL1 (0.34) | IDO1OPRL1CYP17A1RPS6KA3 | |
| SCHEMBL25790654 | 0.74 | CYP11B1 (0.33) | ADRA2AADRA2BADRA2CCYP11B1CYP11B2 | |
| SCHEMBL16132536 | 0.74 | OPRL1 (0.57) | IDO1OPRL1CYP17A1 | |
| SCHEMBL8139062 | 0.73 | OPRL1 (0.40) | OPRL1CYP17A1RPS6KA3CYP11B1CYP11B2 | |
| SCHEMBL24850990 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20220168280-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-02 | — | — | US | disclosed |
| EP-4001269-A1 | BENZOISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | Amgen Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3558955-B1 | BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | AMGEN INC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-11045484-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10988485-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2021-01-14 | — | — | US | disclosed |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-02-20 | — | — | US | disclosed |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190345169-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174501-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | IDO1 3185/4885OPRL1 4722/4885ADRA2A 4541/4885 |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | IDO1 4527/4885OPRL1 4725/4885ADRA2A 4664/4885 |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | IDO1 4577/4885OPRL1 4725/4885ADRA2A 4553/4885 |
| US-11045484-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | IDO1 4527/4885OPRL1 4725/4885ADRA2A 4664/4885 |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | IDO1 4522/4885OPRL1 4692/4885ADRA2A 4556/4885 |
| US-20190345169-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | IDO1 4527/4885OPRL1 4725/4885ADRA2A 4664/4885 |
| US-10988485-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | IDO1 4527/4885OPRL1 4725/4885ADRA2A 4664/4885 |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | IDO1 4527/4885OPRL1 4725/4885ADRA2A 4664/4885 |
| US-20220168280-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | IDO1 4527/4885OPRL1 4725/4885ADRA2A 4664/4885 |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | IDO1 4527/4885OPRL1 4725/4885ADRA2A 4664/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | IDO1 2876/4885OPRL1 4714/4885ADRA2A 4589/4885 |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | IDO1 4579/4885OPRL1 4740/4885ADRA2A 4659/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | IDO1 3855/4885OPRL1 4515/4885ADRA2A 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.